B
Bull
Bull · 25%GCTK
$6.64
Szenariopreis
$4.230
-0.062 (-1.47%)Zum Schluss
Loading chart…
- High
- 4.332
- Open
- 4.200
- VWAP
- 4.25
- Vol
- 178.67K
- Mkt Cap
- 11.01M
- Low
- 4.185
- Amount
- 759.19K
- EV/EBITDA, TTM
- 0.00
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
AI analysis of GlucoTrack Inc (GCTK)
sellGlucoTrack Inc is not a good buy right now due to significant financial losses and a very low stock price. The current price is $0.28, down 92.73% year-to-date, and the company has a negative EPS of -2.65. Additionally, the RSI is at 23.92, indicating the stock is oversold, but this does not outweigh the risks involved.
Bewertungskennzahlen
The current forward P/E ratio for GlucoTrack Inc (GCTK) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for GCTK
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.508-27NASDAQ.COMGlucotrack Announces 1-for-15 Reverse Stock Split
7.508-21NewsfilterLōkahi Therapeutics Renews Collaboration with University of Georgia
8.508-05seekingalphaGlucotrack Secures $5.5M Financing from Institutional Investors
- 8.508-05Newsfilter
Glucotrack Secures $5.5 Million Financing
9.507-31NASDAQ.COMMultiple Companies Report Strong Earnings
GCTK FAQ — answered by Alphio AI
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
GlucoTrack Inc is not a good buy right now due to significant financial losses and a very low stock price. The current price is $0.28, down 92.73% year-to-date, and the company has a negative EPS of -2.65. Additionally, the RSI is at 23.92, indicating the stock is oversold, but this does not outweigh the risks involved.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.